Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

This study has been completed.
Information provided by:
Danish Procalcitonin Study Group Identifier:
First received: September 1, 2005
Last updated: NA
Last verified: February 2005
History: No changes posted

Procalcitonin, a marker of infection has often been compared to clinical pictures as for instance "clinical sepsis". This has given som problems in the interpretation of these studies, because of the lack of good Gold Standards for "clinical sepsis. We have decided to investigate the development from day to day of Procalcitonin in the blood of intensive care patients, compared to the mortality.

Hypothesis: Procalcitonin increase after reaching a certain level predicts mortality in the Intensive Care Unit.

Sepsis - to Reduce Mortality in the Intensive Care Unit

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

Resource links provided by NLM:

Further study details as provided by Danish Procalcitonin Study Group:

Estimated Enrollment: 450
Study Start Date: January 2002
Estimated Study Completion Date: January 2003
  Show Detailed Description


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria: Admitted to the ICU 4131 of Rigshospitalet Copenhagen University Hospital in the year 2002

Exclusion Criteria:

Recent (< 3 months) liver transplantation

Expected admission < 24 h

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00144638

Dept. 4131, Rigshospitalet, Cph University Hosp., DK
Copenhagen, Denmark, DK-2100
Sponsors and Collaborators
Danish Procalcitonin Study Group
Principal Investigator: Lars Heslet, MD, MD.Sc. Dept. 4131, Rigshospitalet, Blegdamsvej 9, DK-2100
  More Information Identifier: NCT00144638     History of Changes
Other Study ID Numbers: DPSG1 
Study First Received: September 1, 2005
Last Updated: September 1, 2005
Health Authority: Denmark: National Board of Health

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes processed this record on May 24, 2016